Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States

References

• Multiple Sclerosis International Federation (MSIF). Atlas of MS 3rd edition. Part 1: mapping multiple sclerosis around the world: key epidemiology findings; 2020. Available from: https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. Accessed September 20, 2022.
   Google Scholar
• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi:10.1177/1352458520970841
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–e1040. doi:10.1212/WNL.0000000000007035
   PubMed Web of Science ®Google Scholar
• Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. doi:10.1101/cshperspect.a028928
   PubMed Web of Science ®Google Scholar
• Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology. 2020;94(24):1088–1092. doi:10.1212/WNL.0000000000009636
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Nichols E; GBD Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–285. doi:10.1016/S1474-4422(18)30443-5
   PubMed Web of Science ®Google Scholar
• Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Health-related quality of life of multiple sclerosis patients: a European multi-country study. Arch Public Health. 2021;79(1):39. doi:10.1186/s13690-021-00561-z
   PubMed Web of Science ®Google Scholar
• Bebo B, Cintina I, LaRocca N, et al. The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs. Neurology. 2022;98(18):e1810–e1817. doi:10.1212/WNL.0000000000200150
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788. doi:10.1212/WNL.0000000000005347
   PubMed Web of Science ®Google Scholar
• Zhang J, Shi S, Zhang Y, et al. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2017;11(11):CD010968. doi:10.1002/14651858.CD010968.pub2
   PubMedGoogle Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase 3 trial. Lancet. 2012;380(9856):1829–1839. doi:10.1016/S0140-6736(12)61768-1
   PubMed Web of Science ®Google Scholar
• Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17(10):696–707. doi:10.3111/13696998.2014.940422
   PubMedGoogle Scholar
• Grand’Maison F, Yeung M, Morrow SA, et al. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Neural Regen Res. 2018;13(11):1871–1874. doi:10.4103/1673-5374.239432
   PubMed Web of Science ®Google Scholar
• Hillert J, Magyari M, Soelberg Sorensen P, et al. Treatment switching and discontinuation over 20 years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021;12:647811. doi:10.3389/fneur.2021.647811
   PubMed Web of Science ®Google Scholar
• Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9(4):250–263. doi:10.1177/1756285616634247
   PubMed Web of Science ®Google Scholar
• Sanofi. AUBAGIO® (teriflunomide) tablets [prescribing information]; 2022. Available from: https://products.sanofi.us/aubagio/aubagio.pdf. Accessed May 3, 2023.
   Google Scholar
• European Medicines Agency. Aubagio (teriflunomide) tablets [summary of product characteristics]; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf. Accessed May 3, 2023.
   Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–1303. doi:10.1056/NEJMoa1014656
   PubMed Web of Science ®Google Scholar
• O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920–930. doi:10.1212/WNL.0000000000002441
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256. doi:10.1016/S1474-4422(13)70308-9
   PubMed Web of Science ®Google Scholar
• Miller AE, Olsson TP, Wolinsky JS, et al. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: results from the TOWER extension study. Mult Scler Relat Disord. 2020;46:102438. doi:10.1016/j.msard.2020.102438
   PubMed Web of Science ®Google Scholar
• Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107–115. doi:10.1016/j.msard.2017.07.006
   PubMed Web of Science ®Google Scholar
• Coyle PK, Khatri B, Edwards KR, et al. Teriflunomide real-world evidence: global differences in the Phase 4 Teri-PRO study. Mult Scler Relat Disord. 2019;31:157–164. doi:10.1016/j.msard.2019.03.022
   PubMed Web of Science ®Google Scholar
• Papp V, Buron MD, Siersma V, et al. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in the Danish Multiple Sclerosis Registry. PLoS One. 2021;16(5):e0250820. doi:10.1371/journal.pone.0250820
   PubMed Web of Science ®Google Scholar
• Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;12:1756286419835077. doi:10.1177/1756286419835077
   Web of Science ®Google Scholar
• Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 2018;26:211–218. doi:10.1016/j.msard.2018.09.017
   PubMed Web of Science ®Google Scholar
• Watson Health. IBM MarketScan Research Databases for life sciences researchers; 2023. Available from: https://www.ibm.com/downloads/cas/OWZWJ0QO. Accessed: January 2, 2023.
   Google Scholar
• Code of Federal Regulations. TITLE 45: PUBLIC WELFARE (subtitle A subchapter A part 46 - protection of human subjects) [§46.104(d)(4)(ii)]; 2018. Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46. Accessed January 19, 2023.
   Google Scholar
• Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data. PLoS One. 2020;15(5):e0231846. doi:10.1371/journal.pone.0231846
   PubMed Web of Science ®Google Scholar
• Raimundo K, Tian H, Zhou H, et al. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv Res. 2013;13:131. doi:10.1186/1472-6963-13-131
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469–476. doi:10.18553/jmcp.2002.8.6.469
   PubMedGoogle Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625. doi:10.3111/13696998.2010.523670
   PubMedGoogle Scholar
• U.S. Bureau of Labor Statistics. CPI Medical care services (2013–2020); 2020. Available from: https://www.bls.gov/cpi/data.htm. Accessed September 20, 2022.
   Google Scholar
• Duquette P, Yeung M, Mouallif S, Nakhaipour HR, Haddad P, Schecter R. A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies. PLoS One. 2019;14(1):e0210417. doi:10.1371/journal.pone.0210417
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13(1):90–98. doi:10.3111/13696990903579501
   PubMedGoogle Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286. doi:10.1212/WNL.0000000000000560
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Johnson BH, Watson C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res. 2013;6:11–20. doi:10.2147/CEOR.S55779
   PubMedGoogle Scholar
• Nicholas J, Boster A, Wu N, et al. Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data. Pharmacoecon Open. 2018;2(1):31–41. doi:10.1007/s41669-017-0035-2
   PubMed Web of Science ®Google Scholar
• Vermersch P, Suchet L, Colamarino R, Laurendeau C, Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017. Mult Scler Relat Disord. 2020;46:102521. doi:10.1016/j.msard.2020.102521
   PubMed Web of Science ®Google Scholar
• Yermakov S, Davis M, Calnan M, et al. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J Med Econ. 2015;18(9):711–720. doi:10.3111/13696998.2015.1044276
   PubMed Web of Science ®Google Scholar
• Lizán L, Comellas M, Paz S, Poveda JL, Meletiche DM, Polanco C. Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Prefer Adherence. 2014;8:1653–1664. doi:10.2147/PPA.S67253
   PubMed Web of Science ®Google Scholar
• Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251–260. doi:10.2147/CEOR.S130334
   PubMed Web of Science ®Google Scholar
• Río J, Tintoré M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012;19(6):899–904. doi:10.1111/j.1468-1331.2011.03648.x
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2
   PubMed Web of Science ®Google Scholar